153 related articles for article (PubMed ID: 16485127)
1. Immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI).
Schmidt J; Patrut EM; Ma J; Jäger D; Knaebel HP; Büchler MW; Märten A
Cancer Immunol Immunother; 2006 Nov; 55(11):1396-405. PubMed ID: 16485127
[TBL] [Abstract][Full Text] [Related]
2. Impact of interferon-alpha in combined chemoradioimmunotherapy for pancreatic adenocarcinoma (CapRI): first data from the immunomonitoring.
Schmidt J; Jäger D; Hoffmann K; Büchler MW; Märten A
J Immunother; 2007 Jan; 30(1):108-15. PubMed ID: 17198089
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma.
Ma JH; Patrut E; Schmidt J; Knaebel HP; Büchler MW; Märten A
World J Gastroenterol; 2005 Mar; 11(10):1521-8. PubMed ID: 15770730
[TBL] [Abstract][Full Text] [Related]
4. A randomized multicentre phase II trial comparing adjuvant therapy in patients with interferon alpha-2b and 5-FU alone or in combination with either external radiation treatment and cisplatin (CapRI) or radiation alone regarding event-free survival - CapRI-2.
Märten A; Schmidt J; Ose J; Harig S; Abel U; Münter MW; Jäger D; Friess H; Mayerle J; Adler G; Seufferlein T; Gress T; Schmid R; Büchler MW
BMC Cancer; 2009 May; 9():160. PubMed ID: 19470159
[TBL] [Abstract][Full Text] [Related]
5. Interferon-alpha enhances antitumor effect of chemotherapy in an orthotopic mouse model for pancreatic adenocarcinoma.
Zhu Y; Tibensky I; Schmidt J; Ryschich E; Märten A
J Immunother; 2008 Sep; 31(7):599-606. PubMed ID: 18600184
[TBL] [Abstract][Full Text] [Related]
6. Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma -- CapRI: study protocol [ISRCTN62866759].
Knaebel HP; Märten A; Schmidt J; Hoffmann K; Seiler C; Lindel K; Schmitz-Winnenthal H; Fritz S; Herrmann T; Goldschmidt H; Krempien R; Mansmann U; Debus J; Diehl V; Büchler MW
BMC Cancer; 2005 Apr; 5():37. PubMed ID: 15826316
[TBL] [Abstract][Full Text] [Related]
7. Combination doxorubicin and interferon-α therapy stimulates immunogenicity of murine pancreatic cancer Panc02 cells via up-regulation of NKG2D ligands and MHC class I.
Wang WJ; Qin SH; Zhang JW; Jiang YY; Zhang JN; Zhao L
Asian Pac J Cancer Prev; 2014; 15(22):9667-72. PubMed ID: 25520086
[TBL] [Abstract][Full Text] [Related]
8. 5-Fluorouracil and interferon-α immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I.
Khallouf H; Märten A; Serba S; Teichgräber V; Büchler MW; Jäger D; Schmidt J
J Immunother; 2012 Apr; 35(3):245-53. PubMed ID: 22421942
[TBL] [Abstract][Full Text] [Related]
9. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma.
Schmidt J; Abel U; Debus J; Harig S; Hoffmann K; Herrmann T; Bartsch D; Klein J; Mansmann U; Jäger D; Capussotti L; Kunz R; Büchler MW
J Clin Oncol; 2012 Nov; 30(33):4077-83. PubMed ID: 23008325
[TBL] [Abstract][Full Text] [Related]
10. Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma.
Zhu Y; Tibensky I; Schmidt J; Hackert T; Ryschich E; Jäger D; Büchler MW; Märten A
J Immunother; 2008 Jan; 31(1):28-33. PubMed ID: 18157009
[TBL] [Abstract][Full Text] [Related]
11. Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy.
Bellone G; Novarino A; Vizio B; Brondino G; Addeo A; Prati A; Giacobino A; Campra D; Fronda GR; Ciuffreda L
Int J Oncol; 2009 Jun; 34(6):1701-15. PubMed ID: 19424589
[TBL] [Abstract][Full Text] [Related]
12. Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro.
Liu W; O'Donnell MA; Chen X; Han R; Luo Y
Cancer Immunol Immunother; 2009 Oct; 58(10):1647-55. PubMed ID: 19214503
[TBL] [Abstract][Full Text] [Related]
13. Influence of interferon-alpha combined with chemo (radio) therapy on immunological parameters in pancreatic adenocarcinoma.
Karakhanova S; Mosl B; Harig S; von Ahn K; Fritz J; Schmidt J; Jäger D; Werner J; Bazhin AV
Int J Mol Sci; 2014 Mar; 15(3):4104-25. PubMed ID: 24608924
[TBL] [Abstract][Full Text] [Related]
14. Human pancreatic carcinoma cells secrete bioactive interleukin-18 after treatment with 5-fluorouracil: implications for anti-tumor immune response.
Carbone A; Rodeck U; Mauri FA; Sozzi M; Gaspari F; Smirne C; Prati A; Addeo A; Novarino A; Robecchi A; Bertetto O; Emanuelli G; Bellone G
Cancer Biol Ther; 2005 Feb; 4(2):231-41. PubMed ID: 15684607
[TBL] [Abstract][Full Text] [Related]
15. The participation of the Fas-mediated cytotoxic pathway by natural killer cells is tumor-cell-dependent.
Mori S; Jewett A; Murakami-Mori K; Cavalcanti M; Bonavida B
Cancer Immunol Immunother; 1997 Jul; 44(5):282-90. PubMed ID: 9247563
[TBL] [Abstract][Full Text] [Related]
16. A dual anti-tumor effect of a combination of interferon-alpha or interleukin-2 and 5-fluorouracil on natural killer (NK) cell-mediated cytotoxicity.
Reiter Z; Ozes ON; Blatt LM; Taylor MW
Clin Immunol Immunopathol; 1992 Jan; 62(1 Pt 1):103-11. PubMed ID: 1370257
[TBL] [Abstract][Full Text] [Related]
17. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
Picozzi VJ; Kozarek RA; Traverso LW
Am J Surg; 2003 May; 185(5):476-80. PubMed ID: 12727570
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292.
Sparano JA; Lipsitz S; Wadler S; Hansen R; Bushunow PW; Kirkwood J; Flynn PJ; Dutcher JP; Benson AB
Am J Clin Oncol; 1996 Dec; 19(6):546-51. PubMed ID: 8931668
[TBL] [Abstract][Full Text] [Related]
19. Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma.
Nukui Y; Picozzi VJ; Traverso LW
Am J Surg; 2000 May; 179(5):367-71. PubMed ID: 10930481
[TBL] [Abstract][Full Text] [Related]
20. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity.
Märten A; von Lilienfeld-Toal M; Büchler MW; Schmidt J
Int J Cancer; 2006 Nov; 119(10):2359-65. PubMed ID: 16929491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
